What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Hepatol Commun · 2021 · PMC8557311 · PMID 34499435

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

showed a trendP = 0.051so close (0.05 < p ≤ 0.1)

( 72 ) Aramchol decreased liver fat and improved liver enzymes, and the 600 mg daily dose showed a trend toward higher NASH resolution rates compared to placebo (16.7% and 5%, respectively, P = 0.051).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.